AsclepiX Appoints Amir Shojaei, PhD, as Chief Scientific Officer and Executive Vice President, Clinical Development

AsclepiX Therapeutics announced the appointment of Amir Shojaei, PhD, as Chief Scientific Officer, Executive Vice President, Clinical Development. Dr. Shojaei has built a career in life sciences as a leader with over two and a half decades of drug development experience, focused on the clinical development, registration and commercialization of biopharmaceuticals and biologics in multiple therapeutic areas.

“Integrins and recognition molecules play a significant role in normal human biology,” Dr. Shojaei said in a company news release.“AsclepiX has identified numerous families of peptides that act as integrin regulators such as that in AXT107 (gersizangitide) with the potential to treat retinal diseases. I’m honored to be working with the AsclepiX team as we progress through phase 1/2a clinical studies in nAMD and DME and in expanding our development pipeline in ophthalmology and beyond.”

AsclepiX CEO, Robert Dempsey, said “I am truly excited to have Amir join AsclepiX given his unparalleled success advancing clinical development programs in ophthalmology.”

Prior to joining, Dr. Shojaei served as the CEO and Chief Development Officer for TherOptix overseeing clinical development and regulatory affairs at TearClear. Dr. Shojaei was Therapeutic Area Head of Ophthalmology at Shire/Takeda. He oversaw all aspects of clinical stage ophthalmic pipeline assets bringing Xiidra from development to approval in the U.S. and in Canada, Mexico, Australia, Switzerland, South Korea, and the Gulf countries.